Targeting a new signaling pathway to improve treatment for obesity-related diabetes
Official title: Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes
Funded at Senseion Therapeutics, INC. · NIH-10490426 · Data updated 2026-11-12
This study is looking at a new way to help people with Type 2 diabetes by testing a special compound that could improve how their body handles insulin and glucose, which might lead to better blood sugar control and fewer complications.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Senseion Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 17, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $990,929 |
| NIH project number | 5R44DK121598-03 |
| Project ID | NIH-10490426 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with obesity-related Type 2 diabetes who struggle with insulin sensitivity and glucose management.
✕Less likely to help
Patients who do not have Type 2 diabetes or those with other forms of diabetes unrelated to obesity may not benefit from this research.
What this research studies
This research investigates a novel ion channel signaling complex called SWELL1, which plays a crucial role in regulating insulin sensitivity and secretion in the body. By using a small molecule modulator, SN-401, the research aims to enhance the function of SWELL1, potentially improving glucose metabolism and insulin response in patients with Type 2 diabetes. The approach includes both laboratory studies and animal models to assess the effectiveness of this treatment in normalizing glucose levels and reducing complications associated with diabetes. Patients may benefit from a new therapeutic option that targets the underlying mechanisms of their condition.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that improves insulin sensitivity and glucose control in patients with obesity-induced Type 2 diabetes.
How similar studies have gone: Other research has shown promise in targeting similar signaling pathways for diabetes treatment, indicating potential for success with this novel approach.
Where this research is happening
-
Senseion Therapeutics, INC.
Saint Louis, United States Active
Researchers
- Principal investigator: Lerner, Daniel J — Senseion Therapeutics, INC.
- Study coordinator: Lerner, Daniel J
Related research
Other NIH-funded projects on the same topics.
-
Ksr2 and obesity-related hearing loss in a mouse model: what it means for veterans
This project studies how obesity and type 2 diabetes affect hearing using a mouse model to identify ways to protect hearing in people with metabolic problems.
-
Epitranscriptomics in obesity and type 2 diabetes
Researchers are studying how gene activity changes in fat tissue and other organs to better understand obesity and type 2 diabetes, with the goal of finding new ideas for treatment.
-
New medicines to help people lose weight safely and protect the pancreatic cells that control blood sugar
A funding opportunity to develop a new pill that helps people lose weight without muscle loss and protects the insulin-producing beta cells in the pancreas.
-
Predicting obesity-related diabetes and wound healing with math models
A math-based model is being built to better understand how obesity drives type 2 diabetes and slow wound healing in adults.
-
Macrophage-targeted drug delivery depot for obesity and type 2 diabetes
A new injectable, long-lasting therapy targets fat‑tighting immune cells to help people with obesity and type 2 diabetes manage their condition.
-
Comparing bariatric (weight‑loss) surgery with GLP‑1 and SGLT‑2 diabetes medicines for people with obesity and type 2 diabetes
This project compares long-term benefits and safety of weight‑loss surgery versus GLP‑1 and SGLT‑2 diabetes medicines for adults who have obesity and type 2 diabetes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.